Search | Clinical Trials Finder

Conditions: Dry Eye Syndromes
Interventions: Punctal plug; Device
Lead sponsor: University of New Mexico; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Infertility
Interventions: Medication Management Software; Device
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older · Female only
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 2
States / cities: Ann Arbor, Michigan • Northville, Michigan

Conditions: Spinal Cord Injuries, Neuropathic Pain
Interventions: VR Game 1, VR Game 2; Other
Lead sponsor: Texas A&M University; Other
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 2
States / cities: Birmingham, Alabama • College Station, Texas

Conditions: Glaucoma, Ocular Hypertension
Interventions: fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution; bimatoprost 0.03% ophthalmic solution, bimatoprost 0.03% ophthalmic solution; hypromellose 0.2% eyedrops; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Smoking
Interventions: Mindfulness, Quit Line; Behavioral
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Chronic Blepharitis
Interventions: Terpinen-4-ol, Placebo; Drug · Other
Lead sponsor: BioTissue Holdings, Inc; Industry
Eligibility: 15 Years to 80 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Fatigue
Interventions: Acupuncture, Placebo Acupuncture; Procedure
Lead sponsor: Alta Bates Summit Medical Center; Other
Eligibility: 18 Years to 64 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Berkeley, California

Conditions: Teen Sexual Health
Interventions: text message intervention; Behavioral
Lead sponsor: Denver Health and Hospital Authority; Other
Eligibility: 13 Years to 18 Years · Female only
Enrollment: 244 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Skin
Interventions: Blue Light Therapy; Device
Lead sponsor: Efforia, Inc; Industry
Eligibility: Not listed
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Attention Deficit Disorder With Hyperactivity
Interventions: Tier 1 Classroom Management, Daily Report Card (DRC), Enhanced DRC (DRC-E), Stimulant; Behavioral · Drug
Lead sponsor: Florida International University; Other
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 2
States / cities: Miami, Florida • Buffalo, New York

Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Locally Advanced Cutaneous Melanoma, Locally Advanced Mucosal Melanoma, Metastatic Acral Melanoma, Metastatic Conjunctival Melanoma, Metastatic Cutaneous Melanoma, Metastatic HER2-Negative Breast Carcinoma, Metastatic Hormone Receptor-Positive Breast Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Mucosal Melanoma, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Recurrent Cutaneous Melanoma, Recurrent HER2-Negative Breast Carcinoma, Recurrent Hormone Receptor-Positive Breast Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Recurrent Mucosal Melanoma, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Unresectable Acral Melanoma, Unresectable Cutaneous Melanoma, Unresectable Lung Non-Small Cell Carcinoma, Unresectable Mucosal Melanoma
Interventions: Neoantigen Peptide Vaccine, Nivolumab, Poly ICLC, Echocardiography Test, Multigated Acquisition Scan, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Positron Emission Tomography, Ruxolitinib; Biological · Drug · Procedure
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Renal Transplant
Interventions: Tacrolimus; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 65 Years
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Dry Eye, Ocular Inflammation
Interventions: Eye wash; Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 153 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Ocular Motility Disorder
Interventions: current standard of care treatments; Procedure
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: Not listed
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2002
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Sexual Trauma
Interventions: Men's MST Group, Present-Centered Group Therapy; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: Male only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: West Los Angeles, California

Conditions: Myopia
Interventions: Software Trainer; Device
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Acute Lymphoblastic Leukemia
Interventions: Neurological Examination/Questionnaires; Other
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 6 Years to 28 Years
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Metastatic Breast Cancer, Advanced Breast Cancer
Interventions: ertumaxomab; Drug
Lead sponsor: Neovii Biotech; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 3
States / cities: Minneapolis, Minnesota • Lebanon, New Hampshire • New York, New York

Conditions: Pain, Postoperative
Interventions: Motrin and narcotic; Drug
Lead sponsor: Cape Fear Valley Health System; Other
Eligibility: 18 Years to 65 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Fayetteville, North Carolina

Conditions: Acute Lymphoblastic Leukemia, BCR-ABL1 Fusion Protein Expression, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive, Recurrent Acute Lymphoblastic Leukemia, t(9;22)
Interventions: Cyclophosphamide, Cytarabine, Dasatinib, Dexamethasone, Doxorubicin, Methotrexate, Prednisone, Vincristine; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2024
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Limbal Stem Cell Deficiency
Interventions: Biopsy to collect limbal epithelial stem cells that will be cultivated into a graft, Cultivation of Limbal epithelial cells into a graft, CALEC Transplant; Procedure · Biological
Lead sponsor: Massachusetts Eye and Ear Infirmary; Other
Eligibility: 18 Years to 89 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Presumed Ocular Histoplasmosis
Interventions: Faricimab Injection [Vabysmo]; Drug
Lead sponsor: Cincinnati Eye Institute, Southwest Ohio; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Cincinnati, Ohio • Dayton, Ohio

Conditions: Amblyopia, Anisometropia, Strabismus
Interventions: Atropine, Patch; Drug · Device
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: Not listed
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2001
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Age-related Macular Degeneration (AMD)
Interventions: Aflibercept, Ranibizumab, Bevacizumab; Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 331,541 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: East Hanover, New Jersey

Search by objective public record fields.

Punctal Plugs and Iodine Related Discomfort

Evaluation of Patient Experience and Quality of Life During In Vitro Fertilization Treatment

Virtual Walking Intervention for Neuropathic Pain in Spinal Cord Injury

Comparing Safety and Efficacy of Combigan® and Lumigan® With Lumigan® Alone in Glaucoma or Ocular Hypertension Subjects Treated With Xalatan®

Meriter Mindfulness Training for Smokers Program and Study

Demodex Blepharitis Treatment Study

Acupuncture for the Treatment of Chronic Post-Chemotherapy Fatigue

Sexual Health Texting Intervention to Support Adolescent Females

See the Impact Beem's Blue Light Therapy Has on Your Skin Health!

Adaptive Response to Intervention (RTI) for Students With ADHD

Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer

Study of Pharmacogenomic-Guided Tacrolimus Dosing and Monitoring in Kidney Transplant Recipients

Closed Eye Neutrophils in Dry Eye Disease

Evaluation and Treatment of Pediatric Eye Diseases

Recovery-oriented Group Therapy for Veteran Men With Military Sexual Trauma

Validation of the Vision Trainer Clinical Decision-Support Software

Neurologic Morbidity and Disability in Acute Lymphoblastic Leukemia Survivors

Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer After Progression on Trastuzumab Therapy

Scheduled or as Needed Pain Regimen?

Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.

Limbal Stem Cell Deficiency (LSCD) Treatment With Cultivated Stem Cell (CALEC) Graft

A Prospective Longitudinal Analysis of Faricimab (Vabysmo 6mg) For Choroidal Neovascularization in Presumed Ocular Histoplasmosis Syndrome

Amblyopia (Lazy Eye) Treatment Study

Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Agerelated Macular Degeneration (AMD) Who Received Anti-VEGF Agents (IRIS Registry)